SCHEMBL2269341

SCHEMBL2269341

CC(=O)c1ccc(-c2ccc(C(=O)O)c(NC(=O)c3ccccc3)c2)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC2 Q92769 4/20 0.71
ACLY P53396 3/20 0.64
DHODH Q02127 1/20 0.62
KMT2A Q03164 4/20 0.59
MEN1 O00255 3/20 0.59
PKM P14618 2/20 0.59
MAPT P10636 2/20 0.59
GRIK1 P39086 1/20 0.59
TDP1 Q9NUW8 1/20 0.59
HDAC1 Q13547 4/20 0.57
HDAC3 O15379 1/20 0.56
NPC1 O15118 1/20 0.56
RAB9A P51151 1/20 0.56
SERPINE1 P05121 1/20 0.54
SUCNR1 Q9BXA5 1/20 0.54
AKR1B10 O60218 1/20 0.52
AKR1B1 P15121 1/20 0.52
AKR1C4 P17516 1/20 0.52
AKR1C3 P42330 1/20 0.52
AKR1C2 P52895 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2273186 0.90 ACLY (0.68) HDAC2ACLYDHODHKMT2AMEN1
SCHEMBL2270222 0.90 DHODH (0.77) HDAC2ACLYDHODHKMT2AMEN1
SCHEMBL2275453 0.90 ACLY (0.76) HDAC2ACLYDHODHKMT2AMEN1
SCHEMBL2271703 0.89 ACLY (0.64) HDAC2ACLYDHODHKMT2AMEN1
SCHEMBL2269268 0.89 ACLY (0.67) HDAC2ACLYDHODHKMT2AMEN1
SCHEMBL12369435 0.88 HDAC2 (0.67) HDAC2ACLYKMT2AMEN1MAPT
SCHEMBL4563581 0.87 ACLY (0.65) HDAC2ACLYDHODHKMT2AMEN1
SCHEMBL2275697 0.86 HDAC1 (0.69) HDAC2ACLYDHODHKMT2AMEN1
SCHEMBL2269909 0.86 ACLY (0.67) HDAC2ACLYDHODHKMT2AMEN1
SCHEMBL2274974 0.86 ACLY (0.67) HDAC2ACLYDHODHKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101094829-B novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO.,LTD. (JP) 2012-02-08 CN disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
CN-101094829-A Novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO LTD (JP) 2007-12-26 CN disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 HDAC2 276/4885ACLY 653/4885DHODH 1469/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.